A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
Phase 1
Completed
NCT06370728
| Condition | Healthy |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Eli Lilly and Company |
|---|
| Status | Completed |
|---|
| Enrollment | 30 participants |
|---|
| Interventions | Orforglipron, Carbamazepine |
|---|
| Start date | May 6, 2024 |
|---|
| Completion date | Jul 23, 2024 |
|---|
| Results posted | Jul 17, 2026 |
|---|
Summary
The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants. The safety and tolerability of orforglipron and carbamazepine when given separately or together will also be evaluated. The study may last up to approximately 77 days for each participant.
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Orforglipron
Day 1 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose); Day 15 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose) · nanograms*hours per milliliter(ng*h/mL)
| Orforglipron + Carbamazepine | 104 ± 26.6 nanograms*hours per milliliter(ng*h/mL) |
|---|
| Orforglipron + Carbamazepine | 18.5 ± 41.7 nanograms*hours per milliliter(ng*h/mL) |
|---|
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Orforglipron
Day 1 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose); Day 15 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose) · nanograms*hours per milliliter(ng*h/mL)
| Orforglipron + Carbamazepine | 93.4 ± 24.6 nanograms*hours per milliliter(ng*h/mL) |
|---|
| Orforglipron + Carbamazepine | 15.8 ± 51.8 nanograms*hours per milliliter(ng*h/mL) |
|---|
PK: Maximum Observed Concentration (Cmax) of Orforglipron
Day 1 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose); Day 15 (Predose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose) · nanograms per milliliter (ng/mL)
| Orforglipron + Carbamazepine | 4.97 ± 31.0 nanograms per milliliter (ng/mL) |
|---|
| Orforglipron + Carbamazepine | 2.22 ± 47.3 nanograms per milliliter (ng/mL) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.